Astrazeneca (AZN) Cash from Discontinued Operations (2009 - 2026)

Astrazeneca's Cash from Discontinued Operations history runs 17 years deep, the most recent figure standing at 3359000000.0 for Q1 2026.

• In Q1 2026, Cash from Discontinued Operations fell 9.53% year-over-year to 3359000000.0; the TTM figure through Mar 2026 stood at 14221000000.0 (up 8.66% YoY), while the FY2025 annual figure was 14575000000.0, up 22.88% from the prior year.
• Cash from Discontinued Operations for Q1 2026 stood at 3359000000.0, up from 2342000000.0 in the prior quarter.
• The five-year high for Cash from Discontinued Operations was 7965000000.0 in Q4 2023, with the low at 1248000000.0 in Q2 2022.
• The 5-year median for Cash from Discontinued Operations is 3232000000.0 (2022), against an average of 3633400000.0.
• The sharpest annual moves came in 2022 and 2024: Cash from Discontinued Operations surged 422.57% in 2022, then sank 63.5% in 2024.
• Astrazeneca's Cash from Discontinued Operations stood at 7410000000.0 in 2022, then advanced by 7.49% to 7965000000.0 in 2023, then tumbled by 63.5% to 2907000000.0 in 2024, then dropped by 19.44% to 2342000000.0 in 2025, then soared by 43.42% to 3359000000.0 in 2026.
• Business Quant data shows AZN's Cash from Discontinued Operations at 3359000000.0 in Q1 2026, 2342000000.0 in Q4 2025, and 5134000000.0 in Q3 2025.